Quest Diagnostics Inc vs NATERA, INC., two Medical Diagnostics stocks. A side-by-side on valuation, growth, margins, returns, and what each price is betting.
Where DGX and NTRA diverge most: on operating margin, DGX reads 15.1% and NTRA reads -13.4%; on net margin, DGX reads 9.2% and NTRA reads -9.1%. The rest of the comparable metrics sit closer together. What DGX's price implies is a bet that sits within the historical range (whole-company basis). The bull and bear cases for each are in their full reports below.
| Metric | DGX | NTRA |
|---|---|---|
| Price | $233.18 | $267.71 |
| Market cap | $26.1B | $37.9B |
| Sector | Medical Diagnostics | Medical Diagnostics |
| Stage | Mature | Growth |
| Implied growth (priced in) | -0.1% | — |
| P/E | 24.8 | — |
| P/B | 3.34 | 21.35 |
| P/S | 2.26 | 15.15 |
| EV/EBITDA | 14.1 | — |
| Revenue growth | +9.9% | +36.4% |
| Operating margin | 15.1% | -13.4% |
| Net margin | 9.2% | -9.1% |
| Return on equity | 13.6% | -12.8% |
| Return on assets | 6.3% | -8.7% |
| Return on invested capital | 9.6% | -13.8% |
| FCF yield | 5.2% | 0.3% |
| Dividend yield | 0.8% | — |
| Debt / equity | 0.72 | 0.05 |
| Current ratio | 1.59 | 2.96 |
| Altman Z (solvency) | 7.70 | 5.81 |
| Piotroski F (quality) | 7 / 9 | 4 / 9 |
Each week boothcheck ranks the stocks whose prices are betting on the most. Read the most stretched bets archive →
boothcheck is also on Android. Get the app on Google Play →
The stronger value is highlighted per metric where one is strictly better on that single number; it is not an overall verdict on either company. For informational and research purposes only. Not investment advice. Not a recommendation to buy, sell, or hold any security. boothcheck is not a registered investment adviser. Past performance does not guarantee future results.